Glutamine Supplementation and Short-term Mortality in Covid-19

The Impact of Glutamine Supplementation Upon the Short-term Mortality of COVID-19 Diseased Patients Admitted in ICU: A Double Blind Randomized Clinical Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04909905

Enrollment

Registered

2021-06-02

Start date

2021-05-30

Completion date

2021-10-30

Last updated

2021-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The aim of this study is to investigate the effect of parenteral L-Glutamine supplementation added to enteral nutrition on short-term ICU mortality (7 days) in Covid-19 diseased patients.

Detailed description

A written informed consent will be taken from the patients or their relatives. Patients with diagnosis of covid-19 with enteral nutrition will be enrolled. Patients will be randomly assigned to receive either standard enteral nutrition (Group EN) or intravenous glutamine supplementation to enteral nutrition (group GN) in a dose of glutamine of 0.4 g/kg/day during ICU stay.

Interventions

DIETARY_SUPPLEMENTStandard enteral nutrition

Standard enteral nutrition according to ICU nutrition protocol for 7 days

COMBINATION_PRODUCTGlutamine

Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of covid-19 diseased patients admitted to the ICU with enteral nutrition.

Exclusion criteria

* Renal failure (creatinine \>180 mmol/l) * Hepatic failure (bilirubin \>40 mmol/l, alanine aminotransferase \>100 U/l and aspartate aminotransferase \>100 U/l) * Severe neutropenia (\<500 cells/mm3) * Patients receiving cytotoxic, radiation and/or steroid therapy * Hemodynamic instability

Design outcomes

Primary

Measure	Time frame	Description
ICU mortality	7 days	Short-term ICU mortality for patients admitted in our ICU & signed for study drugs, who will expire during the study

Secondary

Measure	Time frame	Description
Neutrophil/lymphocyte ratio (NLR)	7 days	Assessing NLR at day zero & day 7 to monitor inflammatory response
D- dimer level	7 days	Assessing D-dimer level at day zero &day 7 to monitor coagulability status
ICU stay	7 days	Period of patients admission in ICU within duration of study

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026